Among 32 matched cohort pairs of breast cancer survivors in the Stockholm-Gotland region (2008–2019), women carrying germline BRCA1/2 mutations experienced cardiovascular disease at roughly half the rate of non-carriers (6.4% vs. 11.2%). Yet multi-state Cox proportional hazards models revealed the apparent protective effect is almost certainly a statistical artifact: BRCA carriers faced more than twice the competing risk of distant metastasis or non-cardiovascular death (22.3% vs. 10.1%), dramatically shrinking the time window in which cardiovascular events could even occur. Cardiovascular events clustered in the first post-diagnosis year, especially in BRCA carriers, reinforcing this truncation effect.
This finding matters because it corrects a potentially misleading signal. Naïve survival analyses that ignore competing risks can falsely suggest disease resistance when, in reality, patients are dying of other causes before a second condition manifests—a classic methodological trap in cancer survivorship research. The study's rigorous multi-state modeling approach is a methodological strength, but the matched subgroups are small, limiting statistical power to detect real cardiovascular differences in long-term survivors. The intriguing note that a subset of long-term BRCA survivors may carry distinct cardiovascular susceptibility profiles deserves dedicated follow-up with larger registries.
As a preprint posted on medRxiv and not yet peer-reviewed, these conclusions could shift after independent scrutiny. For clinicians, the practical takeaway is cautious: do not assume BRCA-carrier status confers cardiovascular protection—surveillance remains warranted, particularly for those who achieve long-term remission.